This trial is testing a new drug in combination with standard chemotherapies to see if it is safe and effective for treating advanced solid tumors.
- Breast Cancer
- Colon Cancer
- Colorectal Cancer
- Lung Cancer
- Kidney Cancer
1 Primary · 3 Secondary · Reporting Duration: Cycle 1 Day 3 and Cycle 2 day 1
Side Effects for
4 Treatment Groups
1 of 4
1 of 4
1 of 4
1 of 4
140 Total Participants · 4 Treatment Groups
Primary Treatment: AZD6244 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18 - 130 · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Infante, Jeffrey R., Roger B. Cohen, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, and Patricia M. LoRusso. 2017. “A Phase I Dose-escalation Study of Selumetinib in Combination with Erlotinib or Temsirolimus in Patients with Advanced Solid Tumors”. Investigational New Drugs. Springer Science and Business Media LLC. doi:10.1007/s10637-017-0459-7.
- LoRusso, Patricia M., Jeffrey R. Infante, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, and Roger B. Cohen. 2017. “A Phase I Dose-escalation Study of Selumetinib in Combination with Docetaxel or Dacarbazine in Patients with Advanced Solid Tumors”. BMC Cancer. Springer Science and Business Media LLC. doi:10.1186/s12885-017-3143-6.
- Patel, Sapna P., Alexander J. Lazar, Nicholas E. Papadopoulos, Ping Liu, Jeffrey R. Infante, Michelle R. Glass, Carol S. Vaughn, et al.. 2012. “Clinical Responses to Selumetinib (AZD6244; Arry-142886)-based Combination Therapy Stratified by Gene Mutations in Patients with Metastatic Melanoma”. Cancer. Wiley. doi:10.1002/cncr.27790.
- Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 Oct;35(5):576-588. doi: 10.1007/s10637-017-0459-7. Epub 2017 Apr 19. Erratum In: Invest New Drugs. 2017 Jul 5;:
- 2007. "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00600496.
Frequently Asked Questions
How many distinct venues is the clinical testing available in?
"Currently, 4 medical sites are actively running this trial. They can be found in Nashville, Detroit and Houston with an additional four other locations available. To reduce any necessary travel arrangements, it is advised to select the site closest to you if one decides to participate." - Anonymous Online Contributor
What criteria must a person meet to be considered for enrolment into this experiment?
"To be considered for this trial, applicants ought to have malignant colorectal tumors and span the age range of 18-130. A maximum of 140 people will ultimately be selected." - Anonymous Online Contributor
What therapeutic purposes is AZD6244 typically employed for?
"AZD6244 has been developed to treat metastatic bladder cancer, as well as various other diseases such as advance directives, small cell lung cancer (SCLC), lymphoma, and Hodgkins." - Anonymous Online Contributor
Is the age criterion for this experiment limited to those younger than 25 years?
"As stated in the inclusion criteria for this clinical trial, participants must be aged between 18 and 130." - Anonymous Online Contributor
How hazardous is AZD6244 for patients who take it?
"AZD6244 has not yet been extensively tested, so its safety rating was set at 1 on our risk scale. This is a Phase 1 trial which implies that there is limited data available to support both efficacy and security." - Anonymous Online Contributor
What further exploration has been conducted regarding AZD6244?
"Presently, there are 147 phase 3 clinical trials being conducted for AZD6244 in 440 active studies. Of these sites, the majority of them can be found in Fuzhou, Fujian Province; however, 30211 centers across the world have been enlisted to partake within this research endeavour." - Anonymous Online Contributor
What is the maximal number of participants being enrolled in this trial?
"Unfortunately, enrollment for this trial has been closed. This clinical study was originally posted on December 14th 2007 and the most recent update was made September 20st 2022. If you are seeking other trials to enroll in, there are 6280 studies involving colon neoplasms with participants being recruited and 440 trials recruiting patients taking AZD6244." - Anonymous Online Contributor
Are there any current opportunities to enroll in this investigation?
"Per the clinicaltrials.gov registry, this trial is no longer recruiting new participants; it was initially posted on December 14th 2007 and its most recent update came in September 20th 2022. Despite that, over 6720 other medical studies are currently open for enrollment." - Anonymous Online Contributor